Data of distinct stromal protein expressions between sarcoma patient-derived models and their primary tumors

Abstract

To examine whether patient-derived sarcoma models recapitulate the heterogeneity seen in patients, proteomic analysis of both sarcoma models with different subtypes and passage numbers and their primary tumors was performed using mass spectrometry. The levels of stromal proteins derived from tumors were lower in patient-derived xenografts (PDXs) and cell lines, and some human stromal proteins were replaced by the corresponding mouse proteins in PDXs.